Latest Oncology News

Frontline Pembrolizumab Noninferior But Not Superior to Frontline Chemo in PD-L1+ Gastric/GEJ Adenocarcinoma

January 21, 2022

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.